Bibliography

4: Pfizer Inc., Press Release, November 9, 2020,
https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-vaccine-candidate-against.
5: Pfizer Inc., Press Release, November 18, 2020,
https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-conclude-phase-3-study-covid-19-vaccine.
6: P. Fernando et al. for the C4591001 Clinical Trial Group (Pfizer), Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine, The New England Journal of Medicine, https://www.nejm.org/doi/pdf/10.1056/NEJMoa2034577?articleTools=true.
7: Moderna Inc., Press Release, November 16, 2020,
https://investors.modernatx.com/news-releases/news-release-details/modernas-covid-19-vaccine-candidate-meets-its-primary-efficacy.
8: Moderna Inc., Press Release, November 30, 2020,
https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-primary-efficacy-analysis-phase-3-cove-study.
9: L.R. Baden et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine, The New England Journal of Medicine,
https://www.nejm.org/doi/10.1056/NEJMoa2035389.
10: AstraZeneca PLC, News Release, 23 November 2020,
https://www.astrazeneca.com/content/dam/az/media-centre-docs/press-releases/2020/AZD1222-HLR-RNS.pdf.
11: M. Voysey et al. (AstraZeneca) Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK, December 8, 2020,
https://doi.org/10.1016/S0140-6736(20)32661-1.
12: G. D'Agostini and A. Esposito, Inferring vaccine efficacies and their uncertainties. A simple model implemented in JAGS/rjags, 19 November 2020,
https://www.roma1.infn.it/~dagos/prob+stat.html#vaccini.
13: A. Fauci at NBC News, November 16, 2020, https://youtu.be/8CG8aI4XCGw?t=32.
14: International Organization for Standardization (ISO), Guide to the expression of uncertainty in measurement, Geneva, Switzerland, 1993,
https://www.bipm.org/en/publications/guides/gum.html.
15: G. D'Agostini, The Waves and the Sigmas (To Say Nothing of the 750 GeV Mirage), arXiv:1609.01668 [physics.data-an].
16: G. D'Agostini, Bayesian Reasoning in Data Analysis. A critical Introduction, World Scientific, 2003.
17: M. Plummer, JAGS: A Program for Analysis of Bayesian Graphical Models Using Gibbs Sampling, Proceedings of the 3rd International Workshop on Distributed Statistical Computing (DSC 2003), March 20–22, Vienna, Austria. ISSN 1609-395X, http://mcmc-jags.sourceforge.net/ .
18: See, e.g.,
J. Cohen, Science, ‘Absolutely remarkable’: No one who got Moderna’s vaccine in trial developed severe COVID-19, November 30, 2020,
https://www.sciencemag.org/news/2020/11/absolutely-remarkable-no-one-who-got-modernas-vaccine-trial-developed-severe-covid-19 (https://www.sciencemag.org/news/2020/11/absolutely-remarkable-no-one
-who-got-modernas-vaccine-trial-developed-severe-covid-19).
D. Grady, New York Times, Moderna Applies for Emergency F.D.A. Approval for Its Coronavirus Vaccine, November 30 2020,
https://www.nytimes.com/2020/11/30/health/covid-vaccine-moderna.html .
Repubblica, Vaccino, Moderna chiede l'autorizzazione all'uso di emergenza alla Fda e all'Ema. L'azienda americana annuncia i risultati della fase 3: “Efficacia pari al 94,1% e fino al 100% nei casi gravi”, November 30, 2020,
https://www.repubblica.it/cronaca/2020/11/30/news/vaccino_i_dati_di_moderna_efficace_al_94_1_e_fino_al_100_nei_casi_gravi_-276437984/ .
E. Cohen, CNN, Moderna applies for FDA authorization for its Covid-19 vaccine, December 1, 2020, https://edition.cnn.com/2020/11/30/health/moderna-vaccine-fda-eua-application/index.html .
19: G. D'Agostini and A. Esposito, Checking individuals and sampling populations with imperfect tests, arXiv:2009.04843 [q-bio.PE].
20: R Core Team (2018), R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria,
https://www.R-project.org/ .
21: M. Plummer, rjags: Bayesian Graphical Models using MCMC.
R package version 4-10, https://CRAN.R-project.org/package=rjags .
22: https://www.gavi.org/vaccineswork/what-difference-between-efficacy-and-effectiveness
23: Bayes, Thomas and Price, Richard An Essay towards solving a Problem in the Doctrine of Chance. By the late Rev. Mr. Bayes, communicated by Mr. Price, in a letter to John Canton, A.M.F.R.S., Philosophical Transactions of the Royal Society of London. 53: 370–418, (1763), https://doi.org/10.1098
24: P.S. Laplace, Mémoire sur la probabilité des causes par les événements”, Mémoire de l'Académie royale des Sciences de Paris (Savants étrangers), Tome VI, p. 621, 1774, https://gallica.bnf.fr/ark:/12148/bpt6k77596b/f32 .
25: P.S. Laplace, Essai philosophique sur les probabilités, 1814,
http://books.google.it/books?id=JrEWAAAAQAAJ. (English quotes from the classical translation by F.W. Truscott and F.L. Emory: https://bayes.wustl.edu/Manual/laplace_A_philosophical_essay_on_probabilities.pdf.)
26: World Health Organization, <<1053>>https://www.who.int/docs/default-source/coronaviruse/risk-comms-updates/update-36-long-term-symptoms.pdf?sfvrsn=5d3789a6_2#: :text=
1: LIGO-Virgo Cumulative Event/Candidate Rate Plot O1-O3,
https://dcc.ligo.org/LIGO-G1901322/public.
2: Denis Y. Logunov et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia, February 2, 2021,
https://doi.org/10.1016/S0140-6736(21)00234-8.
3: AstraZeneca, AZD1222 US Phase III trial met primary efficacy endpoint in preventing COVID-19 at interim analysis, March 22, 2021,
https://www.astrazeneca.com/media-centre/press-releases/2021/astrazeneca-us-vaccine-trial-met-primary-endpoint.html.